There is a trend of minimally invasive surgery in the treatment of benign prostatic hypertrophy (BPH). Studies have examined levels of prostate speci®c antigen (PSA) in patients after open prostatectomy or transurethral resection of prostate (TURP) and noted reset of PSA to lower values after surgery. We reviewed PSA levels in patients after minimally invasive procedures to determine if levels were reset.
Introduction
Transurethral resection of the prostate (TURP) has remained the gold standard for surgical treatment of benign prostatic hypertrophy (BPH) for the past 50 y. Over the past 5 y, newer less invasive treatment methods such as laser prostatectomy, electrovaporization of the prostate (TVP), and transurethral microwave therapy have been utilized to decrease the morbidity and hospitalization time associated with the TURP. These newer treatment modalities do not result in a similar amount of tissue destruction as the TURP. While decreases are noted in prostatic volume there are no quantitative methods to measure the amount of tissue destroyed, as is possible with the surgical specimen after a TURP. To date, no study procedures have presented long-term data regarding prostate-speci®c antigen (PSA) levels in men after undergoing laser prostatectomy or TVP. Marks et al recently reported long-term PSA levels in men after TURP with a mean follow-up of 37 months. 1 Mean PSA velocity was 0.01 ng/ml per y and was unaffected by age, race or amount of tissue removed. The mean PSA level after surgery was 0.85 ng/ml and this average level was maintained through follow-up of patients over a mean of 36 months.
As more minimally invasive therapies for the treatment of BPH become available, it will be necessary to obtain post-operative levels of PSA so that adequate screening can be maintained for the possible development of prostate cancer in these men.
Materials and methods
Three cohorts of men with BPH who underwent either laser prostatectomy, TURP or TVP constituted the population of this study. The laser and TURP patients were part of a randomized prospective trial. 2 The TVP patients were a separate nonrandomized, consecutive group. There were 50 patients in the laser cohort, 50 patients in the TURP group and 20 patients underwent TVP for a total of 120 patients. No patient was included in the study if there was a history of carcinoma of the prostate. All patients underwent pre-operative evaluation including American Urologic Association (AUA) symptom score, uro¯owmetry, pressure¯ow, PSA and transrectal ultrasound for prostate volume. Patients were seen in followup at 3, 6, 12, 18 and 24 months with PSA levels being obtained at each follow-up visit and a prostate volume obtained at 6, 12, 18 and 24 months.
PSA levels were determined by the Hybritech method. The PSA velocity was calculated by utilization of the Carter calculation for all patients with a 2 y follow-up period. 2 One hundred patients were randomized pre-operatively to undergo either laser prostatectomy or TURP. In addition, 20 consecutive patients underwent an electrovaporization procedure. The patients in the TURP group underwent a standard transurethral resection utilizing a Circon/ACMI continuous¯ow resectoscope with video monitoring. The laser cohort had laser ablation performed with a Laserscope KTP: NdYAG laser system with an ADD Stat laser ®ber. TVP was performed with a Circon/ ACMI Vaportrode electrode with a continuous¯ow resectoscope and video monitoring. Transrectal ultrasound was performed on patients within 1 month prior to undergoing the surgical procedure. Serum PSA levels were obtained within 1 month prior to the surgical procedure and at all indicated follow-up visits. All medical therapy was stopped 1 month prior to the procedure. No patient was on ®nasteride pre-operatively. Follow-up visits were at 3, 6, 12, 18 and 24 months with serum PSA levels obtained at each visit. Statistical analysis was performed with commercial software utilizing analysis of variance (ANOVA). All values for the mean are reported AE standard error. Table 1 describes the characteristics for the three cohorts of patients in the study. The mean pre-operative PSA (ng/ ml) was 2.7, 3.2 and 2.9 for the laser, TURP and TVP groups respectively. Mean prostatic volume (cm 3 ) was 32.2, 29.6 and 34.6 for the laser, TURP and TVP patients. Each of the cohorts were comparable in terms of age and race distribution. Table 2 shows the mean PSA levels at 1 and 2 y follow-up for each patient group. The laser and TURP treatment group demonstrated a decreased mean PSA level at year 1 and this was maintained into year 2. Overall, in year 1, the percentage decrease was 7 32% for the laser cohort, 7 46% for the TURP patients and 7 8% for the TVP group. In year 2, the mean percentage decrease was maintained for the laser and TURP groups ( 7 39% and 7 37%, respectively) and further decrease ( 7 21%) for the TVP group. Table 3 shows the average PSA velocity for year 1 and 2 for each of the treatment groups. As expected the TURP group had the greatest decrease in velocity in year 1 as compared to the other treatment modalities. At year 2, the TURP patients continued to have the largest negative velocity as compared to laser and TVP patients but at a slower rate than year 1.
Results
Three patients, two in the TURP cohort and one in the TVP group, were diagnosed with prostate cancer during the study. Of the two patients in the TURP group, one had an average PSA velocity of 0.0 ng/ml at year 1 and 2.0 ng/ml at year 2, and the other patient had an average of 0.5 ng/ml at year 1 and 1.3 ng/ml at year 2. The patient in the TVP group had an average PSA velocity of 0.5 ng/ml year 1 and 1.0 ng/ml at year 2. To date, no patients in the laser cohort have been diagnosed with prostate cancer. The pre-operative PSA levels for these patients were in the normal range but subsequently had an increased PSA velocity in year 2 of follow-up for all three patients.
Discussion
TURP remains the gold standard for surgical treatment of BPH. However, with the advent of numerous minimally invasive treatment modalities such as laser, microwave, thermotherapy, radiofrequency ablation and electrovaporization, the number of TURPs being performed in this country continues to decrease. It has been recognized that patients who have undergone either open prostatectomy or transurethral surgery will experience a marked decline in serum PSA. 1,4 ± 8 As the transition zone is a major site of PSA production, the removal of this tissue does cause a decrease in the serum PSA post-operatively. This study demonstrated there is a similar decrease in post-operative PSA that occurs after treatment with two different types of minimally invasive therapies. The PSA velocity was found to remain zero or negative for the 2 y study period, again in the same range as for TURP patients. As Marks et al reported, the level of PSA after TURP is lower, additionally the new PSA level remained reset at a lower level for up to 5 y post operatively. 1 The PSA velocity in their study, post surgery, was in a range of zero for the follow-up period. The results in this study would con®rm that, with the newer treatment modalities for BPH, a resetting of the PSA level does occur and it remains reset during the follow-up period.
The three patients diagnosed with prostate cancer had pre-and post-treatment PSA levels within the normal range. Additionally, the PSA levels post-treatment were reset to a lower level and the key indication for prostate biopsy was an increased PSA velocity. If the patients had been monitored only according to their new PSA levels without regard to PSA velocity, the diagnosis would have been missed in patients.
These data demonstrate that with these minimally invasive treatment modalities destruction of transition zone tissue does occur, as evidenced by sustained decreased PSA levels. As it has been previously reported that the transition zone is the main source of PSA, laser and electrovaporization treatment would appear to have their main effect in the transition zone in contrast to microwave technology where patients post-procedure have very slight declines in PSA levels. 3, 4 As the number of TURP continues to decline, the number of alternative minimally invasive treatments being performed increases. With these new treatment modalities tissue is not available for histologic examination, therefore, careful follow-up with periodic PSA levels will remain important in this group of patients.
Cetinkaya et al recently published a report on the in¯uence of TURP on free PSA and percentage free PSA in a group of patients with BPH. 5 Serum PSA and free PSA levels measured 24 h after surgery were found to be signi®cantly elevated as compared to pre-operative levels. However, the free/total PSA ratio did not change normally between pre-and post-operative values. It will be interesting to see if this changes over longer follow-up. Free/total PSA ratio may be the preferred measure to follow in post-surgical patients.
Summary
Treatment of BPH by minimally invasive methods such as laser or electrovaporization results in the resetting of PSA levels to a new lower level, which is sustained similarly to that seen with patients treated by TURP. Recognition of these changes is important for the long-term screening of the patients. 
